Asia Pacific Epigenetics Market
Asia Pacific Epigenetics Market by Offering [Enzymes, Kits & Reagents, Software, Services], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Asia Pacific epigenetics market is projected to reach USD 0.97 billion by 2030, up from USD 0.49 billion in 2025, registering a CAGR of 14.6% from 2025 to 2030. Growth in the Asia Pacific epigenetics market is driven by rapidly developing life sciences hubs across China, Japan, and other countries in the Asia Pacific. Oncology and precision medicine programs are scaling up. Strong government genomics initiatives and the expansion of NGS capacity, among other factors, are helping to maintain steady demand for epigenetics kits, reagents, and services.
KEY TAKEAWAYS
-
By CountryThe Japan epigenetics market accounted for a 25.4% revenue share in 2024.
-
By OfferingBy offering, the services segment is expected to register the highest growth rate.
-
By TechnologyBy technology, the next-generation sequencing (NGS) segment accounted for the largest market share in 2024.
-
By MethodBy method, the DNA methylation segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeCompanies such as Thermo Fisher Scientific, Illumina, and Merck KGaA were identified as some of the key players in the Asia Pacific epigenetics market, given their strong market share and product/service footprint.
-
Competitive LandscapeCompanies such as Novogene Co., Ltd, and Abnova Corporation, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The Asia Pacific epigenetics market is experiencing growth, driven by increasing demand for precise biomarker discovery and multi-omics research across oncology, immunology, and precision medicine programs. Use of DNA methylation and chromatin profiling workflows is expanding across drug discovery and translational studies. This momentum is supported by improving research funding, expanding genomics and NGS infrastructure, and a growing size of biopharma pipelines in the region.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Stakeholder impact in the Asia Pacific epigenetics market is largely influenced by the growing focus on precision oncology and personalized care. Advances in NGS, methylation profiling, chromatin analysis, and multi-omics are continually improving sensitivity, throughput, and data quality. The organizations mentioned, including biopharmaceutical and biotech companies, diagnostic labs, CROs, and academic and government research institutes, represent the major user base for epigenetics products in the region. Primarily, these instruments are used for cancer research and drug development, biomarker discovery, patient stratification, and therapy response monitoring.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Growing national precision medicine programs
-
Rapid adoption of NGS and multi-omics aiding growth of epigenetics
Level
-
Uneven infrastructure creating quality and access gap
Level
-
Growth in regional biopharma pipelines for epigenetics in drug R&D
Level
-
Gaps in bioinformatics and interpretation capacity
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing national precision medicine programs
Several Asia Pacific countries are funding precision medicine at the national level. Singapore’s National Precision Medicine program is designed to translate Asian genomics into care. Australia is investing through the Genomics Health Futures Mission to integrate genomics into practice. Japan has structured cancer genomics through a national hospital network and a data platform. These initiatives expand sample collections, datasets, and routine sequencing. Epigenetics is growing alongside, as methylation and chromatin profiling are part of multi-omics studies.
Restraint: Uneven infrastructure creating quality and access gap
The Asia Pacific has global hubs, but capacity is unevenly distributed. Some markets lack consistent sample logistics, biobanks, and high-quality lab operations. These gaps affect assay repeatability and clinical confidence. The Pacific region genomics access roadmap identifies infrastructure and system readiness as key levers for broader access.
Opportunity: Growth in regional biopharma pipelines for epigenetics in drug R&D
The Asia Pacific biopharma is expanding its oncology and immunology programs. Epigenetics supports target discovery, patient stratification, and response monitoring. Japan’s cancer genomics ecosystem enables structured data use for research and drug development. China’s precision medicine policy environment is also facilitating deeper genomics integration, with clear governance expectations. These developments are driving demand for end-to-end epigenomics platforms in discovery and translational studies. They also support partnerships among kit vendors, CROs, and hospital networks.
Challenge: Gaps in bioinformatics and interpretation capacity
Epigenomics outputs are data-intensive. They require a skilled workforce for QC, pipeline tuning, and biological interpretation. Studies on precision medicine in Asia indicate gaps in bioinformatics capabilities and workforce readiness. Workforce-focused reviews also emphasize the need for sustained training and capacity building.
ASIA PACIFIC EPIGENETICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
The team at Children’s Hospital of Soochow University profiled chromatin regulation in AML using ChIP-seq and CUT&Tag. Samples were sequenced on BGISEQ 2000 (BGI) and NovaSeq 6000 (Novogene) | Faster mapping of transcriptional control points. Stronger confidence in target biology and pathways. Better biomarker hypotheses for patient stratification and response monitoring |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Asia-Pacific epigenetics market ecosystem includes strong consumables and kit suppliers for DNA methylation and chromatin workflows. It also includes NGS, single-cell, and automation vendors that streamline sample preparation, sequencing, and lab throughput. A growing number of bioinformatics and software providers support epigenomic pipelines, multi-omics integration, and secure data handling for large, multi-country datasets. Major end users include biopharma and biotech companies, universities and public research institutes, and increasingly hospitals and diagnostic labs adopting epigenetics in precision oncology, biomarker-led drug development, and other applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Asia Pacific epigenetics market, By Offering
In 2024, the products subsegment dominated the Asia Pacific epigenetics market, as most epigenetics workflows are consumable-heavy and scale directly with sample volumes. Labs repeatedly purchase bisulfite conversion kits, methylation library prep and enrichment reagents, ChIP/CUT&Tag antibodies, and chromatin assay reagents across academic institutes, CROs, and biopharma R&D programs. This repeat demand is keeping products ahead of services in overall market contribution.
Asia Pacific epigenetics market, By Technology
In 2024, NGS dominated the Asia Pacific epigenetics market by delivering high-throughput, data-focused profiling for both methylation sequencing and chromatin readouts at scale. Large cohort studies and multi-omics projects in oncology increasingly favor sequencing-based epigenetics for deeper resolution and better data integration; this trend is supporting the growth of NGS in the Asia Pacific epigenetics market.
Asia Pacific epigenetics product market, By Application
In 2024, oncology dominated the Asia Pacific epigenetics market, as epigenetic alterations play a key role in tumor biology, disease subtyping, and biomarker discovery. DNA methylation and chromatin signatures are widely used to support patient stratification, treatment response tracking, and resistance research across translational studies in major Asia Pacific research hubs.
REGION
China to be the fastest-growing country in the Asia Pacific Epigenetics market during the forecast period
In 2024, China is the fastest-growing market within the Asia-Pacific epigenetics market, supported by its large and fast-growing biopharma sector and a strong base of universities, research institutes, and top-tier hospitals running high-throughput genomics and epigenomics programs. The country’s expanding sequencing capacity, strong government-backed genomics initiatives, and growing CRO ecosystem are accelerating adoption of NGS-based methylation profiling and chromatin analysis, thus supporting growth of the epigenetics market in the country.
ASIA PACIFIC EPIGENETICS MARKET: COMPANY EVALUATION MATRIX
In the Asia Pacific epigenetics market matrix, Thermo Fisher Scientific (Star) leads due to its broad, end-to-end portfolio that supports DNA methylation and chromatin workflows, from sample prep and library preparation to sequencing-compatible reagents, instruments, and downstream analysis enablement. Its strong regional distribution network and deep presence across Asia Pacific academic institutes, CROs, and biopharma R&D sites support its repeat consumables demand. PacBio (Emerging Leader) is building momentum in Asia Pacific as long-read sequencing gains traction for more data-driven epigenetics, including methylation detection and complex genomic contexts that can be difficult to resolve with short reads.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific, Inc. (US)
- Merck KGaA (Germany)
- Illumina, Inc. (US)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (US)
- Novogene Co., Ltd. (China)
- Abnova Corporation (Taiwan)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.44 Billion |
| Market Forecast in 2030 (Value) | USD 0.97 Billion |
| Growth Rate | CAGR of 14.6% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | Japan, China, India, Australia, South Korea, and Rest of Asia Pacific |
WHAT IS IN IT FOR YOU: ASIA PACIFIC EPIGENETICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| India competitive landscape |
|
|
RECENT DEVELOPMENTS
- October 2024 : Agency for Science, Technology and Research (US) and Macrogen, Inc. (South Korea) PacBio collaborated with Agency for Science, Technology and Research and Macrogen to launch a state-of-the-art sequencing lab in Singapore to advance genomics innovation in Asia. The facility will leverage PacBio's Revio system to support research in human health, biodiversity, and precision medicine, establishing Singapore as a hub for high-throughput long-read and short-read sequencing technologies.
- October 2024 : Illumina, Inc. launched MiSeq i100 and MiSeq i100 Plus Systems, offering rapid, scalable, and user-friendly NGS capabilities enhanced by room-temperature kit handling, greener packaging, and integrated analytics designed to meet evolving lab demands across research and clinical domains.
- May 2024 : QIAGEN launched the QIAseq Multimodal DNA/RNA Library Kit, enabling seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS).
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research involved extensively using secondary sources, directories, and databases to gather valuable information for analyzing the Asia Pacific Epigenetics Market . In-depth interviews were conducted with various key respondents, including industry leaders, subject-matter experts (SMEs), C-level executives of major market players, and industry consultants, to obtain and verify critical qualitative and quantitative data and to evaluate the market's growth prospects. The global market size, estimated through secondary research, was then triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the Asia Pacific Epigenetics Market . The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochmistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences (NIEHS), Canadian Institutes of Health Research (CIHR), Genome Canada, and Central Drugs Standard Control Organisation (CDSCO); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the Asia Pacific Epigenetics Market , which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Asia Pacific Epigenetics Market . These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were used whenever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Market Definition
Epigenetics involves assessing individual behaviors and environmental factors that may influence gene functions. Unlike genetic changes, epigenetic modifications can be reversed and do not alter the DNA sequence. The report provides both qualitative and quantitative analyses of various products and services used in epigenetics research by end users such as academic and research institutions, pharmaceutical and biotechnology companies, and hospitals and clinics.
Stakeholders
- Contract research organizations (CROs)
- Contract development and manufacturing organizations (CDMOs)
- Pharmaceutical & biopharmaceutical companies
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the Asia Pacific Epigenetics Market by offering, method, technology, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall Asia Pacific Epigenetics Market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product launches, agreements, partnerships, acquisitions, and R&D activities
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the Asia Pacific Epigenetics Market .
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Epigenetics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Asia Pacific Epigenetics Market